Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine

Samankaltaisia teoksia

• Priming with a Simplified Intradermal HIV-1 DNA Vaccine Regimen followed by Boosting with Recombinant HIV-1 MVA Vaccine Is Safe and Immunogenic: A Phase IIa Randomized Clinical Trial
  Tekijä: Munseri, Patricia. J., et al.
  Julkaistu: (2015)
• Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen
  Tekijä: Bauer, Asli, et al.
  Julkaistu: (2017)
• High prevalence of ECG variations and abnormalities in young and healthy TaMoVac 01 HIV vaccine trial volunteers from Tanzania
  Tekijä: Mann, PJ, et al.
  Julkaistu: (2012)
• Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen
  Tekijä: Podola, L, et al.
  Julkaistu: (2012)
• P14-03. HIV-specific T-lymphocyte proliferative responses induced by a multigene multiclade HIV-1 DNA/MVA heterologous vaccine in Tanzanian volunteers
  Tekijä: Aboud, S, et al.
  Julkaistu: (2009)